Ormeval surfaces publicly reported development activity and pairs it with a transparent, fully auditable modelled baseline. Market-size, epidemiology, pricing and revenue figures are computed deterministically and traced to their public sources, never scraped, never confidential, never AI-invented.
Trial data are courtesy of ClinicalTrials.gov, a service of the U.S. National Library of Medicine. Our copy was processed by ClinicalTrials.gov on 2026-09-28 and is refreshed on a schedule; for the authoritative and current record, see ClinicalTrials.gov. We do modify registry content: trial records are resolved across development code, INN and brand, grouped into programmes and classified by stage. Those modifications are described in full on our methodology page. Ormeval asserts no proprietary right in the database and does not represent it as anything other than a United States Government database.
Data provided by the U.S. Food and Drug Administration (https://open.fda.gov), used under its CC0 1.0 Universal dedication. The NLM and the FDA do not endorse Ormeval, and label-derived fields are not a substitute for the official FDA label.
Revenue & milestones from company IR, SEC/EDGAR, FDA, EMA; trials & labels live from ClinicalTrials.gov and openFDA. Not financial advice.